Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... (PRWEB) November 20, 2014 The November ... available as an open access journal featuring the following ... fluorescent proteins to preserve photoresponsiveness in the retina , ... fluorescent in situ hybridization using chromogenic substrates in zebrafish ... DNA, RNA, and protein electrophoresis , Nuclear ...
(Date:11/21/2014)... November 21, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... ferrocyanide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
(Date:11/18/2014)... Calif. , Nov. 18, 2014 Cord ... platinum sponsor of the 10th Annual World Stem Cell Summit, ... medicine stakeholders. The 2014 World Stem Cell Summit will be ... San Antonio, Texas . The ... and development of lifesaving cures and therapies, convening the most ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
... the potential to revolutionize the world of sensors: motion, ... micro scale down to the nano requires finding a ... gadgetry. In a paper appearing in ... Zhiping Xu of MIT,s Department of Civil and Environmental ...
... BASF filed a lawsuit in the United States District Court ... Pont de Nemours and Company) for infringement of BASF,s patented ... Specifically, DuPont,s Optimum GAT corn product incorporates BASF,s patented promoter ... toward an herbicide class known as AHAS or ALS inhibitors. ...
... to accelerate basic research and drive personalized medicine. , ... today announced that it has signed an agreement with ... Rosetta Biosoftware, a business unit of Rosetta Inpharmatics LLC, ... The deal allows Microsoft to incorporate genetic, genomic, metabolomic ...
Cached Biology Technology:Biomimetic-engineering design can replace spaghetti tangle of nanotubes in novel material 2BASF Sues DuPont for Patent Infringement 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
(Date:11/7/2014)... BURBANK, Calif. , Nov. 7, 2014  In conjunction ... Burbank Police Departments, The Community Foundation of the ... BURBANK DNA JUSTICE PROJECT," a $250,000 initiative to ... successful initial phase. In its first six months of existence, ... desperately needed evidence support for local law enforcement. ...
(Date:11/6/2014)... PITTSBURGH--Speed is an asset for a predator. Except when that ... The tiger beetle, relative to its size, is the fastest ... 120 body lengths per second (at about five miles per ... To take the sprinting gold from the tiger beetle, a ... BUT! The tiger beetle has a problem. At peak speeds, ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2The tiger beetle: Too fast to see 2
... Researchers at the University of Illinois at Chicago College ... on the nervous system to create the devastation of Huntington,s ... Nature Neuroscience online. The researchers were able to ... called JNK3, which is expressed only in neurons and, further, ...
... soil microbe that uses chemical warfare to fight off ... of its arsenal, researchers report, making use of an ... known to do: break a non-activated carbon-carbon bond in ... in the journal Nature , provides the first ...
... play a role in growth of some types of ... cancer development, say researchers from the Lombardi Comprehensive Cancer ... findings, presented at the annual meeting of the Endocrine ... this protein, known as Stat5a, may be different in ...
Cached Biology News:Huntington's disease deciphered 2Huntington's disease deciphered 3Researchers describe 'implausible' chemistry that produces herbicidal compound 2Dual role in breast tissue for a protein involved in leukemia 2
... Pulser Xcell microbial system, 100 to ... for electroporation of bacterial and fungal ... unit, PC module for exponential decay ... cuvettes (5 each of 0.1 and ...
... solution. In PBS containing ... other proprietary stabilizers; 0.2 ... to stabilize activity of ... at high conjugate dilutions ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
... on Macintosh operating systems to predict ... sequence up to 3,200 bases, which ... and GC clamps for mutation detection ... constant denaturing gel electrophoresis (CDGE), and ...
Biology Products: